Will Kaback
speaker
1,313 appearances
13 recordings
1 series
first heard Aug 2026
last heard 5d ago
Will Kaback’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 13 in all, peaking in Sep 2026 with 12.
Appearances
The rising adoption of GLP-1s has coincided with U.S.
obesity rates decreasing from 39.9% in 2022 to 36.8% in 2026.
Users like Governor Pritzker have reported health improvements after lifetime struggles with weight management.
Pritzker said he has lost 80 pounds in the two years since he began taking a GLP-1 medication.
Under current federal law, Medicare and Medicaid mostly cover GLP-1s if prescribed for diabetes, but new initiatives are exploring potential coverage for obesity.
In July, Medicare launched a pilot program to provide certain GLP-1s to some Medicare Part D beneficiaries.
The Trump administration has also sought to negotiate reduced prices for the drugs for Medicare and Medicaid recipients, as well as U.S.
consumers paying for them out of pocket.
The side effects of the drugs are still being studied, and a March 2026 study by the Washington University School of Medicine found that people who start and then stop GLP-1 treatments experience a, quote, meaningful increase in the risk of major cardiovascular events compared with those remaining on the medication, end quote.
Another study identified a biological mechanism that may be causing users to regain lost weight after they stop taking the medication.
Separately, hundreds of consumers have sued GLP-1 manufacturers Novo Nordisk and Eli Lilly, alleging that the drug increases the risk of a condition that causes blindness.
Today, we'll share views from the right and the left on the rising prevalence of GLP-1s, and then editor Audrey Moorhead gives her take.
Many on the right praise the innovation that led to GLP-1s and their benefits.
Some argue that government coverage would raise the drugs prices.
Others note the potential health consequences of taking the drugs.
The Washington Post editorial board argued the promise of weight loss drugs keeps growing.
Eli Lilly announced in May that the highest dose of its new weight loss drug helped people shed more than 30% of their body weight, on par with gastric bypass surgery.
Eli Lilly's innovation promises to unlock surgery-free treatment for people with a severely high body mass index, for whom weight loss medications have not been a durable option.
Studies have found that users of these drugs cut their grocery expenditures, especially on calorie-dense snacks and processed foods.
That could mean reducing future healthcare costs on chronic illnesses such as diabetes and cardiovascular disease.
Showing 21–40 of 1,313 · page 2 of 66
← Previous
Next →